tailieunhanh - Báo cáo y học: "A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. | Journal of Immune Based Therapies and Vaccines BioMed Central Original research A phase I randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy Gareth AD Hardy41 Nesrina Imami41 Mark R Nelson2 Ann K Sullivan2 Ron Moss3 Marlén MI Aasa-Chapman4 Brian Gazzard2 and Frances M Gotch 1 Open Access Address Department of Immunology Imperial College London Chelsea and Westminster Hospital 369 Fulham Road London SW10 9NH UK 2Department of HIV GU Medicine Imperial College London Chelsea and Westminster Hospital 369 Fulham Road London SW10 9NH UK 3Immune Response Corporation Carlsbad CA USA and 4Wohl Virion Centre Windeyer Institute of Medical Sciences UCL London W1T 4JF UK Email Gareth AD Hardy - Nesrina Imami - Mark R Nelson - Ann K Sullivan - Ron Moss - shotdoc92130@ Marlén MI Aasa-Chapman - Brian Gazzard - Frances M Gotch - Corresponding author tEqual contributors Published II April 2007 Received 29 September 2006 Journal of Immune Based Therapies and Vaccines 2007 5 6 doi 1476-8518-5-6 Accepted 11 April 2007 This article is available from http content 5 1 6 2007 Hardy et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Fully functional HIV-1-specific CD8 and CD4 effector T-cell responses are vital to the containment of viral activity and disease progression. These responses are lacking in HIV-1-infected patients with progressive disease. We attempted to augment fully functional HIV-1-specific CD8 and CD4 effector T-cell responses in patients with advanced .